{
  "pmcid": "12432660",
  "sha256": "8e93e3c8e9e90ff682ad3bf7391ced1e5d3d1f4d6a36d2381a09ea2ecd507f9d",
  "timestamp_utc": "2025-11-09T23:37:54.917887+00:00",
  "model_used": "gpt-4o",
  "readability": {
    "flesch_kincaid": 12.731007751937987,
    "reading_ease": 29.316899224806235,
    "word_count": 258
  },
  "consort_scores": {
    "rubric_version": "v3.0-2025-10-14",
    "items": {
      "Title": {
        "score": 1,
        "evidence": "Randomised Controlled Trial on Post-Operative Radiotherapy in Resected NSCLC"
      },
      "Trial_Design": {
        "score": 1,
        "evidence": "Participants were randomly assigned to receive either PORT using modern techniques or no PORT."
      },
      "Participants": {
        "score": 1,
        "evidence": "This multicenter randomised controlled trial included patients with resected NSCLC."
      },
      "Intervention": {
        "score": 2,
        "evidence": "Participants were randomly assigned to receive either PORT using modern techniques or no PORT."
      },
      "Objective": {
        "score": 1,
        "evidence": "This trial assesses the impact of PORT on disease-free survival (DFS) and overall survival (OS)."
      },
      "Method_Outcome": {
        "score": 2,
        "evidence": "The primary outcome was DFS over a 5-year period."
      },
      "Randomisation_Allocation": {
        "score": 2,
        "evidence": "Randomisation was computer-generated, and allocation was concealed."
      },
      "Blinding": {
        "score": 1,
        "evidence": "Blinding was not applied to patients or clinicians, but outcome assessors were blinded."
      },
      "Number_Randomised": {
        "score": 2,
        "evidence": "A total of 501 patients were randomised, with 250 in the PORT group and 251 in the control group, recruited between 2010 and 2021."
      },
      "Number_Analysed": {
        "score": 1,
        "evidence": "In the intention-to-treat analysis, PORT significantly reduced mediastinal recurrence."
      },
      "Result_Outcome": {
        "score": 3,
        "evidence": "PORT significantly reduced mediastinal recurrence (HR 0.71, 95% CI: 0.51–0.97) but did not improve DFS or OS (HR 1.02, 95% CI: 0.68–1.52)."
      },
      "Harms": {
        "score": 1,
        "evidence": "Adverse events were more frequent in the PORT group, with grade 3 or 4 cardiopulmonary toxicities in 11% compared to 5% in the control group."
      },
      "Trial_Registration": {
        "score": 1,
        "evidence": "Trial registration: NCTXXXXXXX"
      },
      "Funding": {
        "score": 1,
        "evidence": "Funding: Supported by [Funding Source]."
      }
    },
    "total_score": 20,
    "max_score": 25
  }
}